Agenus (NASDAQ: AGEN) reported Q4 EPS of ($0.40), $0.12 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $6.67 million.

"We are rapidly advancing with the discovery and clinical development of our innovative I-O agents," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "In the past year, we entered into an important partnership with Gilead, delivered 6 INDs, and confirmed benefit in the majority of patients treated with our lead CTLA-4 and PD-1 antibodies. Our next steps will target submission and commercial launchreadiness for our first two antibodies."

For earnings history and earnings-related data on Agenus (AGEN) click here.